Axsome Therapeutics (AXSM) Gross Profit (2022 - 2026)

Axsome Therapeutics has disclosed Gross Profit across 5 years of filings, most recently posting $176.5 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $176.5 million, up 58.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $655.8 million (up 136.68% YoY), and the FY2025 annual result was $591.0 million, up 67.72% from the prior year.
• Gross Profit came in at $176.5 million for Q1 2026 at Axsome Therapeutics, down from $183.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $183.7 million in Q4 2025 to a low of -$10.0 million in Q4 2024.
• The 5-year median for Gross Profit is $73.9 million (2024), against an average of $80.7 million.
• Across the five-year window, Gross Profit sank 115.61% in 2024 and surged 1934.13% in 2025, its largest moves.
• Axsome Therapeutics' Gross Profit stood at $22.1 million in 2022, then surged by 190.54% to $64.2 million in 2023, then tumbled by 115.61% to -$10.0 million in 2024, then soared by 1934.13% to $183.7 million in 2025, then decreased by 3.92% to $176.5 million in 2026.
• The last three Gross Profit figures came in at $176.5 million (Q1 2026), $183.7 million (Q4 2025), and $159.1 million (Q3 2025), per Business Quant data.